MJH was the legal advisor to Captor Therapeutics S.A. in connection with Captor's IPO - the initial public offering of Captor shares and the admission and introduction of the shares to trading on a regulated market operated by WSE.
IPO amounted to PLN 184 million and is the biggest biotech IPO in WSE history. IPO attracted great interest - the reduction in the individual investors' tranche was 92%. On 19 April 2021 Captor will be listed on the WSE - the first listing of existing shares and rights to new issue shares. Captor's IPO is the first IPO in Europe of a company using the groundbreaking Targeted Protein Degradation technology.
Captor is a rapidly growing Swiss-Polish biopharmaceutical company based in Wrocław, Poland. The company operates in the Wrocław Technology Park, where it has modern laboratories equipped with high-end research equipment. Captor is focused on the discovery and development of breakthrough drug candidates using TPD.
MJH provided comprehensive legal advice to Captor on IPO. The transaction was led by Maciej Wróblewski (Partner) and Wojciech Grabowski (Senior Associate). Anna Skuza (Partner) and Anna Wądołowska (Senior Associate) from the employment law team as well as Tomasz Rutkowski (Partner) and Artur Szczepaniak (Senior Associate) from the corporate and intellectual property (IP/IT) team were also involved in the preparation of IPO and ongoing support.